Moderna (MRNA) Tops Q1 EPS by 48c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Moderna (MRNA) PT Raised to $135 at RBC Capital
May 3, 2024 6:45 AM EDTRBC Capital analyst Luca Issi raised the price target on Moderna (NASDAQ: MRNA) to $135.00 (from $125.00) while maintaining a Outperform rating.
The analyst comments "Bottom line was a beat primarily on lower OpEx. Guide was reiterated ($4b revenue and $8.1b costs), and we like... More
Moderna (MRNA) PT Raised to $95 at Morgan Stanley
May 2, 2024 4:14 PM EDTMorgan Stanley analyst Matthew Harrison raised the price target on Moderna (NASDAQ: MRNA) to $95.00 (from $89.00) while maintaining a Equalweight rating.
The analyst comments "Generally in line quarter, looking ahead the next catalysts for the stock are RSV vaccine PDUFA date May 12 (followed... More
Moderna (MRNA) beats estimates in Q1 2024, targets RSV vaccine launch in fall
May 2, 2024 6:44 AM EDTModerna Inc. (NASDAQ: MRNA) reported first-quarter earnings and revenue that came ahead of analyst expectations, sending its shares 1.5% higher in premarket trading Thursday.
The drugmaker posted a loss per share of $3.07 for the quarter, better than the $3.55 per share loss expected by analysts. Revenue rose to $167 million, significantly higher than the consensus projection of $94.28... More
